Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), comprising the full 44-amino acid sequence with a trans-3-hexenoic acid modification that confers enhanced stability against enzymatic degradation. It is one of the most thoroughly characterised GHRH analogues available as a research compound.
Research has focused on its ability to stimulate pituitary somatotroph cells to release growth hormone in a physiologically relevant, pulsatile manner, and its downstream effects on circulating IGF-1 levels and lipid metabolism parameters. Preclinical and clinical research models have investigated its potential in visceral adipose tissue quantification studies and lipodystrophy-associated metabolic disturbances.
Tesamorelin is frequently used in hypothalamic-pituitary axis research protocols, particularly in studies examining GHRH receptor binding kinetics, feedback regulation mechanisms, and the relationship between GH secretion and metabolic endpoints. Its well-defined pharmacokinetic profile makes it a preferred GHRH analogue for controlled endocrine research.
Format: Lyophilised powder | Purity: ≥99% by HPLC | For Research Use Only
